

Cereno Scientific to present at Aktiedagen in Gothenburg on May 15, 2023

Cereno Scientific (XSAT: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company will present at the event Aktiedagen, organized by Aktiespararna on Monday, May 15, 2023, in Gothenburg.

Sten R. Sörensen, Chief Executive Officer (CEO) at Cereno, and Björn Dahlöf, Chief Medical Officer (CMO) will participate in the event. The company will be presented at 17:15-17:40 on May 15, 2023. The event is held at Hotel Gothia Towers, Mössans Gata 24, in Gothenburg, and is also live-streamed.

More information can be found on the organizer's website: <https://www.aktiespararna.se/tv>.

For further information, please contact:

Jonas Fogelberg, Interim CFO
Email: info@cerenoscientific.com
<http://www.cerenoscientific.com/>

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist and has documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.